FDA Fast-Tracks AI for Hearts: Machine Learning Gets Class II Nod
Published Date: 9/11/2026
Rule
Summary
The FDA is officially putting cardiovascular machine learning notification software into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new heart health tech. The new rules took effect on September 11, 2026, but have been in place since August 3, 2023, making life simpler for developers and patients alike.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Class II Rule May Improve Patient Access
The FDA has classified cardiovascular machine learning-based notification software as Class II (special controls), effective September 11, 2026, with the classification applicable on August 3, 2023. FDA states this classification will reduce regulatory burdens and "enhance patients' access to beneficial innovative devices," which may make these non-diagnostic cardiovascular decision‑support tools more available to patients.
Premarket 510(k) Required for Devices
FDA states cardiovascular machine learning-based notification software remains subject to premarket notification under section 510(k) of the FD&C Act. Companies seeking to market this Class II device must submit a 510(k) unless FDA later determines the device type should be exempt under section 510(m).
New Special Controls Add Testing & Labeling Rules
Manufacturers must meet new special controls including clinical performance testing using real‑world test datasets (independent from training data), subgroup analyses, objective performance measures, and a test dataset that includes a minimum of three geographically diverse sites. They must also perform software verification/validation, human factors assessment, and include detailed labeling (limitations, warnings, supported sensors, and expected minimum performance).
De Novo Classification Enables 510(k) Predicates
FDA states that because this device was classified via the De Novo process, the device type can serve as a predicate for future devices of the same type, allowing subsequent sponsors to use the less burdensome 510(k) pathway instead of De Novo or premarket approval. FDA notes this consequence in its discussion of the De Novo classification process.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-18607, Fisheries of the Northeastern United States; Greater Atlantic Region Catch Share Cost Recovery Program Updates
Starting October 13, 2026, fishermen in the Atlantic Sea Scallop, Golden Tilefish, and Surfclam/Ocean Quahog catch share programs will see simpler rules and lower costs. These updates make managing fishing quotas easier and ensure fees fairly cover program costs without exceeding 3% of fish value. If you’re part of these programs, get ready for smoother sailing and timely fee payments to keep your permits active!
Next: 2026-18623, Fisheries of the Northeastern United States; Atlantic Bluefish Fishery; Quota Transfer From New Jersey to North Carolina
New Jersey is sharing 250,000 pounds of its 2026 bluefish catch limit with North Carolina to help balance fishing opportunities this year. This change runs from September 10 to December 31, 2026, letting North Carolina catch more bluefish while keeping the total catch fair and sustainable. Fishermen in both states will feel the impact, but it helps keep the fishery healthy and on track.